The T genotype of the MGMT C>T (rs16906252) enhancer single-nucleotide polymorphism (SNP) is associated with promoter methylation and longer survival in glioblastoma patients

European Journal of Cancer

Volumn 49, Issue 2, 2013, Pages 360-368

  McDonald, K L ^a   Rapkins, R W ^a   Olivier, J ^b   Zhao, L ^a   Nozue, K ^a   Lu, D ^a   Tiwari, S ^a   Kuroiwa Trzmielina, J ^a   Brewer, J ^b   Wheeler, H R ^b   Hitchins, M P ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Glioblastoma; Methylation; MGMT; Single nucleotide polymorphism; Survival; Temozolomide

Indexed keywords

BEVACIZUMAB; CIS ACTING ELEMENT; ISOCITRATE DEHYDROGENASE 1; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONTROLLED STUDY; DNA METHYLATION; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GLIOBLASTOMA; HAPLOTYPE; HETEROZYGOTE; HUMAN; HUMAN CELL; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; PYROSEQUENCING; SALVAGE THERAPY; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION INITIATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; COHORT STUDIES; COMBINED MODALITY THERAPY; DACARBAZINE; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; GENOTYPE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84872099058     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.08.012     Document Type: Article

References (27)

1. M. Esteller, S.R. Hamilton, and P.C. Burger Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia Cancer Res 59 4 1999 793 797
2. M.E. Hegi, A.C. Diserens, and S. Godard Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide Clin Cancer Res 10 6 2004 1871 1874
3. M.E. Hegi, A.C. Diserens, and T. Gorlia MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 352 10 2005 997 1003
4. B.M. Costa, C. Caeiro, and I. Guimaraes Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: a Portuguese multicentre study Oncol Rep 23 6 2010 1655 1662
5. A.A. Brandes, E. Franceschi, and A. Tosoni Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status Cancer 115 15 2009 3512 3518
6. A.A. Brandes, E. Franceschi, and A. Tosoni MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients J Clin Oncol 26 13 2008 2192 2197
7. G.J. Kitange, B.L. Carlson, and M.A. Schroeder Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts J Neurooncol 11 3 2009 281 291
8. H.S. Friedman, T. Kerby, and H. Calvert Temozolomide and treatment of malignant glioma Clin Cancer Res 6 7 2000 2585 2597
9. W.P. Roos, and B. Kaina DNA damage-induced apoptosis: from specific DNA lesions to the DNA damage response and apoptosis Cancer Lett 2012 [Epub ahead of print]
10. J. Felsberg, N. Thon, and S. Eigenbrod Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas Int J Cancer 129 3 2011 659 670
11. M. Esteller Epigenetic lesions causing genetic lesions in human cancer: promoter hypermethylation of DNA repair genes Eur J Cancer 36 18 2000 2294 2300
12. M. Esteller CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future Oncogene 21 35 2002 5427 5440
13. G. Reifenberger, B. Hentschel, and J. Felsberg Predictive impact of MGMT promoter methylation in glioblastoma of the elderly Int J Cancer 131 2012 1342 1350
14. W. Stummer, U. Nestler, and F. Stockhammer Favorable outcome in the elderly cohort treated by concomitant temozolomide radiochemotherapy in a multicentric phase II safety study of 5-ALA J Neurooncol 103 2011 361 370
15. S. Ogino, A. Hazra, and G.J. Tranah MGMT germline polymorphism is associated with somatic MGMT promoter methylation and gene silencing in colorectal cancer Carcinogenesis 28 9 2007 1985 1990
16. N.J. Hawkins, J.H. Lee, and J.J. Wong MGMT methylation is associated primarily with the germline C>T SNP (rs16906252) in colorectal cancer and normal colonic mucosa Mod Pathol 22 12 2009 1588 1599
17. L.S. Kristensen, H.M. Nielsen, and H. Hager Methylation of MGMT in malignant pleural mesothelioma occurs in a subset of patients and is associated with the T allele of the rs16906252 MGMT promoter SNP Lung Cancer 71 2 2011 130 136
18. S. Leng, A.M. Bernauer, and C. Hong The A/G allele of rs16906252 predicts for MGMT methylation and is selectively silenced in premalignant lesions from smokers and in lung adenocarcinomas Clin Cancer Res 17 7 2011 2014 2023
19. I.L. Candiloro, and A. Dobrovic Detection of MGMT promoter methylation in normal individuals is strongly associated with the T allele of the rs16906252 MGMT promoter single nucleotide polymorphism Cancer Prev Res (Phila) 2 10 2009 862 867
20. L.C. Harris, J.S. Remack, and T.P. Brent Identification of a 59 bp enhancer located at the first exon/intron boundary of the human O6-methylguanine DNA methyltransferase gene Nucleic Acids Res 22 22 1994 4614 4619
21. R. Stupp, W.P. Mason, and M.J. van den Bent Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 10 2005 987 996
22. P. Bady, D. Sciuscio, and A.C. Diserens MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status Acta Neuropathol 2012 [Epub ahead of print]
23. S. Nobusawa, T. Watanabe, and P. Kleihues IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas Clin Cancer Res 15 19 2009 6002 6007
24. C.A. Payne, S. Maleki, and M. Messina Loss of prostaglandin D2 synthase: a key molecular event in the transition of a low-grade astrocytoma to an anaplastic astrocytoma Mol Cancer Ther 7 10 2008 3420 3428
25. R. Stupp, M.E. Hegi, and B. Neyns Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma J Clin Oncol 28 16 2010 2712 2718
26. I. Zawlik, S. Vaccarella, and D. Kita Promoter methylation and polymorphisms of the MGMT gene in glioblastomas: a population-based study Neuroepidemiology 32 1 2009 21 29
27. J. Felsberg, M. Rapp, and S. Loeser Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients Clin Cancer Res 15 21 2009 6683 6693